丙型肝炎病毒载量检测不到与全关节置换术后转归改善相关
多中心回顾性研究纳入2005年1月至2018年4月接受初次全关节置换术的丙型肝炎病毒(HCV)感染患者289例,分为病毒载量检测不到组(118例)和可检测到组(171例)。可检测到病毒载量组手术时间更长、术中失血更多、住院时间更长、术后感染更多、翻修风险更高;Kaplan-Meier分析显示检测不到组生存趋势更好但未达统计学显著(P=0.17)。
要点
- 可检测到HCV病毒载量组手术时间133.9 vs 109.2分钟,术中失血298.4 vs 219.5 mL,住院4.0 vs 2.9天。
- 可检测到病毒载量组术后感染11.7% vs 4.2%,翻修TJA风险12.9% vs 5.1%。
- Kaplan-Meier显示检测不到病毒载量组生存趋势更好(P=0.17),未达统计学显著。
核心结论
- 可检测到HCV病毒载量的全关节置换术患者手术时间更长、术中失血更多、住院时间更长,且更可能发生感染和需要翻修全关节置换术。
- 失血、住院时间和翻修率结果应谨慎解读,因存在混杂因素。
- 作者认为HCV病毒载量是可改变的危险因素,可降低感染和翻修手术风险。
- 血清HCV病毒载量与转归不相关。
研究设计与样本
- 多中心回顾性研究,纳入2005年1月至2018年4月期间诊断为HCV并接受初次全关节置换术的所有患者。
- 按病毒载量分为检测不到组(118例全关节置换术)和可检测到组(171例全关节置换术),共289例全关节置换术。
- 以翻修全关节置换术为终点计算Kaplan-Meier生存率,并对病毒载量特征进行亚组分析。
主要发现
- 可检测到病毒载量组手术时间133.9 vs 109.2分钟,术中失血298.4 vs 219.5 mL,住院时间4.0 vs 2.9天(均为可检测到组 vs 检测不到组)。
- 可检测到病毒载量组术后感染11.7% vs 4.2%,翻修全关节置换术风险12.9% vs 5.1%(均为可检测到组 vs 检测不到组)。
- Kaplan-Meier分析显示检测不到病毒载量组生存趋势更好(P=0.17)。
- 对低和高病毒载量的亚组分析未发现转归差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 失血、住院时间和翻修率结果应谨慎解读,因存在混杂因素。
- Kaplan-Meier分析显示检测不到病毒载量组生存趋势更好但P=0.17,未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous reports establish that infection with hepatitis C virus (HCV) predisposes total joint arthroplasty (TJA) recipients to poor postoperative outcomes. The purpose of the present study is to assess whether variation in HCV VL influences perioperative outcomes following TJA. METHODS: A multicenter retrospective review of all patients diagnosed with HCV who underwent primary TJA between January 2005 and April 2018 was conducted. Patients were stratified into 2 cohorts: (1) patients with an undetectable VL (U-VL) and (2) patients with a detectable VL (D-VL). Kaplan-Meier survivorship analysis was calculated with revision TJA as the end point. Subanalysis on the VL profile was done. RESULTS: A total of 289 TJAs were included (U-VL:118 TJAs; D-VL:171 TJAs). Patients in the D-VL cohort had longer operative times (133.9 vs 109.2 minutes), higher intraoperative blood loss (298.4 vs 219.5 mL), longer inpatient hospital stays (4.0 vs 2.9 days), more postoperative infections (11.7% vs 4.2%), and an increased risk for revision TJA (12.9% vs 5.1%). Kaplan-Meier demonstrated that the U-VL cohort trended toward better survivorship (P = .17). On subanalysis of low and high VL, no difference in outcomes was appreciated. CONCLUSION: TJA recipients with a detectable HCV VL have longer operative times, experience more intraoperative blood loss, have longer hospital length of stay, and are more likely to experience infection and require revision TJA. The blood loss, hospital length of stay, and revision rate findings should be interpreted with caution, however, as there are confounding factors. Our findings suggest that HCV VL is a modifiable risk factor that, can reduce the risk of infection and revision surgery. Additionally, serum HCV VL was not correlated with outcomes.
引用
- Novikov D, Feng JE, Anoushiravani AA, et al. Undetectable Hepatitis C Viral Load Is Associated With Improved Outcomes Following Total Joint Arthroplasty. J Arthroplasty. 2019. PMID: 31351854. doi:10.1016/j.arth.2019.06.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。